International AIDS Vaccine Initiative (IAVI) donations received

This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of December 2019. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.

Table of contents

Basic donee information

We do not have any donee information for the donee International AIDS Vaccine Initiative (IAVI) in our system.

Donee donation statistics

Cause areaCountMedianMeanMinimum10th percentile 20th percentile 30th percentile 40th percentile 50th percentile 60th percentile 70th percentile 80th percentile 90th percentile Maximum
Overall 19 5,000,000 11,921,312 50,000 165,343 1,000,000 1,199,081 2,793,404 5,000,000 7,543,362 21,869,468 27,774,402 29,838,000 49,903,728
Global health 19 5,000,000 11,921,312 50,000 165,343 1,000,000 1,199,081 2,793,404 5,000,000 7,543,362 21,869,468 27,774,402 29,838,000 49,903,728

Donation amounts by donor and year for donee International AIDS Vaccine Initiative (IAVI)

Donor Total 2017 2016 2015 2014 2013 2012 2011 2007 2006
Bill and Melinda Gates Foundation (filter this donee) 226,504,927.00 30,733,149.00 88,592,655.00 2,000,000.00 2,199,081.00 62,656,436.00 4,000,000.00 7,543,362.00 5,000,000.00 23,780,244.00
Total 226,504,927.00 30,733,149.00 88,592,655.00 2,000,000.00 2,199,081.00 62,656,436.00 4,000,000.00 7,543,362.00 5,000,000.00 23,780,244.00

Full list of donations in reverse chronological order (19 donations)

DonorAmount (current USD)Amount rank (out of 19)Donation dateCause areaURLInfluencerNotes
Bill and Melinda Gates Foundation2,793,404.0082017-10-25Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to provide general operating support for HIV vaccine research and product development capacity at IAVI’s Design and Development Laboratory; Aid type: Core support to NGOs, other private bodies, PPPs and research institutes. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation27,774,402.00162017-10-13Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to support the preparation of clinical materials, execution of toxicology studies and data analyses for CAVD investigators towards development of an HIV/AIDS vaccine; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation165,343.0022017-08-09Global health/Health policy and administrative managementhttps://iatiregistry.org/publisher/bmgf-- to develop on behalf of the Global Health Clinical Consortium a training program for study coordinators working on clinical trials addressing major public health concerns in Lower-Middle-Income Country (LMIC) settings; Aid type: Other technical assistance. Affected regions: Africa.
Bill and Melinda Gates Foundation1,000,000.0042016-11-29Global health/Health policy and administrative managementhttps://iatiregistry.org/publisher/bmgf-- to foster exploration and innovation needed to identify, develop and deliver the right global health products to those most in need; Aid type: Contributions to specific-purpose programmes and funds managed by international organisations (multilateral, INGO). Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation21,869,468.00142016-10-13Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to advance development and conduct a phase 1 clinical trial with VSV G-Env.BG505, a new HIV Env vaccine based on a novel live chimeric virus; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation29,424,936.00172016-08-11Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to advance the CAVD-supported projects through the translational stage and into clinical evaluation, ultimately resulting in successful new HIV/AIDS interventions; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation578,711.0032016-07-12Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to facilitate communications and interactions among the parties composing the CAVD, in the belief that collaborative approaches will accelerate the discovery and development of an HIV vaccine; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation29,838,000.00182016-04-26Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to support the preparation of clinical materials, execution of toxicology studies and data analyses for CAVD investigators towards development of an HIV/AIDS vaccine; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation5,881,540.00112016-03-10Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to support an independent preclinical efficacy study and continued analysis of a promising experimental HIV vaccine with significant potential to advance into human clinical testing; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation2,000,000.0072015-10-20Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to support the International AIDS Vaccine Initiative for the Design and Development Lab; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation1,199,081.0062014-11-11Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to sustain and increase political support and financing for HIV vaccine research and development from European Union institutions and key Member States to help accelerate product development by ensuring a robust pipeline of vaccine candidates; Aid type: Contributions to specific-purpose programmes and funds managed by international organisations (multilateral, INGO). Affected regions: South of Sahara.
Bill and Melinda Gates Foundation1,000,000.0042014-05-08Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- To foster exploration and innovation needed to identify, develop and deliver the right global health products to those most in need.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation12,752,708.00132013-11-05Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to provide core services across the HIV vaccine development process. Vaccine Product Development Center. Investment start date: 11/5/2013 to end date: 8/30/2016. Grantee name: International AIDS Vaccine Initiative (IAVI); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation49,903,728.00192013-11-05Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to demonstrate that an HIV ENV based immunogen(s) can be designed to elicit bnAbs in humans and has the potential to prevent HIV infection.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation4,000,000.0092012-10-25Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to provide general operating support. IAVI General Operating Support Grant. Investment start date: 10/25/2012 to end date: 10/31/2013. Grantee name: International AIDS Vaccine Initiative (IAVI); Aid type: Core support to NGOs, other private bodies, PPPs and research institutes. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation7,543,362.00122011-11-07Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to advance two novel replicating HIV vaccines through clinical development. HIV Vaccine Clinical Candidates based on Replication-Competent Viral Vectors that Preferentially Replicate in Lymphoid Tissues. Investment start date: 11/7/2011 to end date: 10/31; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation5,000,000.00102007-08-02Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to establish a program to search for new innovative, potentially high risk, ideas/technologies that may offer promise to the HIV vaccine research and development field; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation50,000.0012006-10-24Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to fund a conference called Stop Cervical Cancer: Accelerating Global Access to HPV Vaccines; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation23,730,244.00152006-06-21Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to design, test and develop safe, effective and affordable novel HIV/AIDS vacccine candidates that elicit potent, durable and protective T cell responses; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.